Clinical trials: Melanoma Stage III
Melanoma
Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma
This is a study of a melanoma vaccine. Study participants will have melanoma that invaded deeply and spread to lymph nodes or another location.
- Trial name
- NCT00184067
- Testing
- Montanide ISA 51
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Southern California
Melanoma Stage III, Melanoma Stage IV
A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment
This is an open-label, randomized, multi-site, Phase II, interventional trial designed to evaluate the efficacy, tolerability, and safety of BNT111 + cemiplimab in anti-programmed death protein 1 (PD-1)/anti-programmed death…
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma
- Trial name
- NCT04526899
- Testing
- BNT111, Cemiplimab
- Where
- 49 sites in United States, Australia and 5 more
- Volunteers
- 184 people
- Sponsor
- BioNTech SE
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
This phase I/II trial studies how well genetically modified therapeutic autologous lymphocytes (patient's own white blood cells) followed by aldesleukin work in treating patients with stage III melanoma or melanoma that has…
- Conditions
- Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
- Trial name
- NCT01740557
- Testing
- Aldesleukin, CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes, Cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from a patient's dendritic cells and tumor cells may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00085488
- Testing
- autologous tumor cell vaccine, therapeutic autologous dendritic cells
- Where
- United States
- Sponsor
- Dartmouth-Hitchcock Medical Center
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Stage III Melanoma, Stage IV Melanoma
Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors
This is a study of transfusion of TBX-3400 in patients with stage III and IV melanoma resistant or refractory to Immune Checkpoint Inhibitors.
- Trial name
- NCT03385486
- Testing
- TBX-3400
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- Taiga Biotechnologies, Inc.
Malignant Melanoma
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
The purpose of this study is to determine the safety and tolerability of treatment with BMS-936558 (MDX-1106) in combination with Ipilimumab (BMS-734016) when given at the same time or as a sequenced regimen in subjects with…
- Trial name
- NCT01024231
- Testing
- BMS-936558 (MDX1106-04), Ipilimumab
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
myDC/pDC in Stage III Melanoma Patients
This is an interventional study to test the immunogenicity of combined adjuvant myDC and pDC vaccination versus adjuvant myDC or pDC vaccination alone in stage III melanoma patients.
- Trial name
- NCT02574377
- Testing
- A: myDC vaccination, B: pDC vaccination, C: combined myDC/pDC vaccination
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Intraocular Melanoma, Melanoma (Skin)
Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells.
- Trial name
- NCT00027742
- Testing
- pegylated interferon alfa, temozolomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill…
- Trial name
- NCT00002854
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- City of Hope Medical Center
Recurrent Melanoma, Stage IIIB Melanoma
Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
This phase II trial studies trametinib in treating patients with melanoma with v-Raf murine sarcoma viral oncogene homolog B (BRAF) non-V600 mutations that has spread to other places in the body.
- Conditions
- Recurrent Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
- Trial name
- NCT02296112
- Testing
- trametinib, laboratory biomarker analysis, pharmacological study
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Metastatic Melanoma
Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01005472
- Testing
- sunitinib malate, temozolomide
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Melanoma Stage I, Melanoma Stage III
Adjuvant Therapy of Skin Melanoma With Alpha Interferon and Naderin
The goal of this clinical trial is to learn if adding alpha interferon to standard treatment works to prevent skin melanoma from coming back after surgery.
- Conditions
- Melanoma Stage I, Melanoma Stage III, Melanoma Stage II, Skin Melanoma
- Trial name
- ATSMAIN (NCT07671495)
- Testing
- Surgical resection, Adjuvant Radiotherapy, interferon alfa
- Volunteers
- 278 people
- Sponsor
- MIPO Clinic
Malignant Melanoma
Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC
Evaluation of the efficacy, safety and biologic effects of neo-adjuvant treatment with vemurafenib + cobimetinib + atezolizumab in patients with limited metastasis of melanoma in stage IIIC/IV melanoma.
- Trial name
- NEO-VC (NCT02303951)
- Testing
- Vemurafenib, Cobimetinib, Atezolizumab
- Where
- 7 sites in France, Germany
- Volunteers
- 47 people
- Sponsor
- University Hospital Tuebingen
Intraocular Melanoma
Vaccine Therapy in Treating Patients With Melanoma of the Eye
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells and decrease the recurrence of melanoma of the eye.
- Trial name
- NCT00036816
- Testing
- MART-1 antigen, NA17-A antigen, gp100 antigen
- Where
- 2 sites in Belgium, Denmark
- Volunteers
- 13 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Melanoma Stage III, Melanoma Stage IV
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
This research study is studying different immunotherapy regimens as a possible treatment for stage III or IV resectable melanoma.
- Trial name
- NCT04007588
- Testing
- Nivolumab, BMS-986205, Ipilimumab
- Where
- 2 sites in United States
- Sponsor
- Dana-Farber Cancer Institute
Melanoma (Skin)
Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy together with resiquimod may make a stronger immune response and prevent or delay the…
- Trial name
- NCT00470379
- Testing
- resiquimod
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Advanced Malignant Solid Neoplasm, Recurrent Melanoma
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
This phase I trial studies the side effects and best dose of sorafenib tosylate when given together with riluzole in treating patients with solid tumors or melanoma that has spread to other places in the body and usually cannot…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Melanoma, Refractory Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7
- Trial name
- NCT01303341
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Riluzole
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Vaccination of Melanoma Patients With Dendritic Cells Loaded With Allogeneic Apoptotic-Necrotic Melanoma Cells
Background: Sixteen melanoma patients (1 stage IIC, 8 stage III, and 7 stage IV) were treated in a Phase I study to evaluate safety and immune responses, with a vaccine (DC/Apo-Nec) composed of autologous dendritic cells (DCs)…
- Trial name
- NCT00515983
- Testing
- DC/Apo-Nec
- Where
- Argentina
- Volunteers
- 16 people
- Sponsor
- José Mordoh, M.D., Ph.D.
Hepatocarcinoma, Lung Cancer
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
This trial was designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by trans-artery/intra-tumor infusion of PD1/PDL1 antibody and/or CTLA4 antibody ipilimumab plus…
- Conditions
- Hepatocarcinoma, Lung Cancer, Melanoma, Renal Cancer
- Trial name
- NCT03755739
- Testing
- Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University